Recent news coverage provides sector and market context relevant to biotech and technology industries but lacks direct company-specific updates for NovaBay Pharmaceuticals.

• Recent business news includes broader biotech sector developments and market conditions but does not provide direct updates on NovaBay Pharmaceuticals' operations or financials [N4].
• No recent company-specific news or announcements were identified in the latest business news feed, limiting visibility into current strategic or operational milestones [N4].
• The latest SEC filings include a 10-K/A annual report filed on April 29, 2026, and a 10-Q quarterly report filed on July 30, 2026, which provide the most recent financial disclosures [S1][S2].

The company's strong liquidity ratios as of mid-2026 suggest it has sufficient cash resources to support its operations and potential development activities. The biotech sector context in recent news indicates ongoing interest and activity in related companies, which could be relevant to NovaBay's strategic positioning. The company's ability to manage its net losses and leverage its cash position could be a positive factor for operational continuity.

The significant net loss reported for the quarter ending June 30, 2026, and negative earnings per share highlight ongoing financial challenges. The lack of recent revenue data and limited disclosure on product development or commercialization activities reduce visibility into the company's business model sustainability. Risk factors are referenced but not detailed, which limits assessment of potential operational or market risks. The absence of direct recent company-specific news may indicate limited public developments or market engagement.

The available information does not provide explicit details on NovaBay Pharmaceuticals' competitive advantages or intellectual property portfolio. The company's strong liquidity position may support ongoing operations and development efforts, but visibility into its product pipeline, market position, or proprietary technology is limited based on the current disclosures.

• Financial Losses: The company reported a net loss of $41,070,000 for Q2 2026, indicating ongoing financial challenges.
• Limited Revenue Disclosure: Recent revenue figures are not disclosed, with the last reported revenue being $46,000 in Q1 2015, limiting visibility into current business performance.
• Risk Factor Disclosure: Risk factors are referenced from the 2025 Annual Report but are not detailed in the latest quarterly filing, limiting current risk assessment.
• Operational Visibility: There is limited public information on the company's product pipeline, commercialization efforts, or strategic initiatives.

• NovaBay Pharmaceuticals, Inc. is a publicly traded company with ticker NBY.
• As of June 30, 2026, the company reported cash and cash equivalents of $6,968,000 and current assets of $8,095,000.
• Current liabilities as of June 30, 2026, were $270,000, resulting in a very strong current ratio of 29.98 and a cash ratio of 25.81, indicating strong liquidity.
• The company reported a net loss of $41,070,000 for the quarter ending June 30, 2026, with basic and diluted earnings per share of -$1.32.
• Revenue data is limited, with a historical figure of $46,000 reported for Q1 2015; no recent revenue figures are disclosed in the latest filings.
• Risk factors are referenced from the 2025 Annual Report as amended, but specific details are not included in the latest quarterly filing.
• Recent business news includes industry context such as biotech sector developments and broader market conditions, but no direct company-specific news was identified in the recent news business feed.
• The latest SEC filings include a 10-K/A annual report filed on April 29, 2026, and a 10-Q quarterly report filed on July 30, 2026.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.